Monitoring shifts in political rhetoric toward universal healthcare and drug pricing is critical for private insurers.

Stock fell 32% due to systemic issues in the Medicare Advantage sector.

The stock experienced the largest drop of 21% because its heavy concentration in Medicare Advantage makes it one of the companies most exposed to the negative financial impact of the low payment rate decision.

Stock fell as much as 21% due to a proposed Medicare Advantage rate increase of only 0.09%, which is insufficient to cover rising healthcare costs and squeezes profit margins.

Negatively impacted by a White House proposal to keep Medicare Advantage payment rates almost flat, which directly translates to lower profits for insurers.

Fell 11% in after-hours trading due to a negative proposed rule change for Medicare Advantage, which is a core part of its business.

The company is heavily exposed to Medicare Advantage, where recent rule changes have severely damaged profitability, making it a company investors should be wary of.

Described as a 'cleaner story' and a less risky alternative to UNH. The company has done a 'terrific job' offsetting headwinds from the V28 revision, as its exposure is more manageable.